Cardiovascular Systems to Webcast Fiscal 2013 Second-Quarter Earnings Conference Call Wednesday, Jan. 30

  Cardiovascular Systems to Webcast Fiscal 2013 Second-Quarter Earnings
  Conference Call Wednesday, Jan. 30

                 Live Webcast at 3:45 p.m. CT (4:45 p.m. ET)

Business Wire

ST. PAUL, Minn. -- January 25, 2013

Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of
its fiscal 2013 second-quarter conference call on Wednesday, Jan. 30, 2013, at
3:45 p.m. CT (4:45 p.m. ET). David L. Martin, president and chief executive
officer, and Laurence L. Betterley, chief financial officer, will discuss the
company’s results for its fiscal second quarter ended Dec. 31, 2012, and its
financial outlook. The company will issue a post-market earnings release on
Jan. 30.

To access the live webcast, go to the investor section of the company’s
website,, on the day of the conference call and click on the
webcast icon. A webcast replay will be available beginning at 5:45 p.m. CT the
same day.

To participate in the conference call, dial (888) 680-0860 and enter 21740396.
Please dial in at least 10 minutes prior to the call. To pre-register for the
call, log on to the following website: When
joining the call, pre-registered participants can enter their PIN code, and
other participants can press *0 to reach the operator, or wait on the line for
operator assistance.

If you do not have access to the Internet and want to listen to an audio
replay of the conference call, dial (888) 286-8010 and enter access number
63349889. The audio replay will be available beginning at 5:45 p.m. CT on
Wednesday, Jan. 30, 2013, through 11 p.m. CT on Wednesday, Feb. 6, 2013.

About Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device
company focused on developing and commercializing innovative solutions for
treating vascular and coronary disease. The company’s Orbital Atherectomy
Systems treat calcified and fibrotic plaque in arterial vessels throughout the
leg in a few minutes of treatment time, and address many of the limitations
associated with existing surgical, catheter and pharmacological treatment
alternatives. The U.S. FDA granted 510(k) clearance for the use of the
Diamondback Orbital Atherectomy System in August 2007. To date, nearly 100,000
of CSI’s devices have been sold to leading institutions across the United
States. CSI has also commenced its ORBIT II Investigational Device Exemption
clinical trial to evaluate the safety and effectiveness of its orbital
technology in treating coronary arteries. The coronary system is limited by
federal law to investigational use and is currently not commercially available
in the United States.

For more information, visit the company’s website at


Cardiovascular Systems, Inc.
Investor Relations, 651-259-2800
Padilla Speer Beardsley Inc.
Marian Briggs, 612-455-1742
Matt Sullivan, 612-455-1709
Press spacebar to pause and continue. Press esc to stop.